Effects of oral iron chelator deferasirox on human malignant lymphoma cells

Korean Journal of Hematology

Volumn 47, Issue 3, 2012, Pages 194-201

  Choi, Jong Gwon ^a   Kim, Jung Lim ^b   Park, Joohee ^a   Lee, Soonwook ^a   Park, Seh Jong ^a   Kim, Jun Suk ^a   Choi, Chul Won ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Apoptosis; Deferasirox; Malignant lymphoma

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 9; DEFERASIROX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84874077087     PISSN: 17387949     EISSN: 20929129     Source Type: Journal    
DOI: 10.5045/kjh.2012.47.3.194     Document Type: Article

References (30)

1. Zhang AS, Enns CA. Iron homeostasis: recently identified proteins provide insight into novel control mechanisms. J Biol Chem 2009;284:711-5.
2. Andrews NC. Forging a field: the golden age of iron biology. Blood 2008;112:219-30.
3. De Domenico I, McVey Ward D, Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol 2008;9:72-81.
4. Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR. Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res 2006;12:6876-83.
5. Kalinowski DS, Yu Y, Sharpe PC, et al. Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J Med Chem 2007;50:3716-29.
6. Triantafyllou A, Liakos P, Tsakalof A, et al. The flavonoid quercetin induces hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits cell proliferation by depleting intracellular iron. Free Radic Res 2007;41:342-56.
7. Gharagozloo M, Khoshdel Z, Amirghofran Z. The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine. Eur J Pharmacol2008;589:1-7.
8. Chaston TB, Lovejoy DB, Watts RN, Richardson DR. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 2003;9:402-14.
9. Choudhari SR, Khan MA, Harris G, et al. Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod. Mol Cancer Ther 2007;6:112-21.
10. Valle P, Timeus F, Piglione M, et al. Effect of different exposures to desferrioxamine on neuroblastoma cell lines. Pediatr Hematol Oncol 1995;12:439-46.
11. Brard L, Granai CO, Swamy N. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecol Oncol 2006;100:116-27.
12. Messa E, Carturan S, Maffè C, et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 2010;95: 1308-16.
13. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004;6:203-8.
14. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 1998;8:297-303.
15. Zhang SQ, Kovalenko A, Cantarella G, Wallach D. Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity 2000;12:301-11.
16. Bubici C, Papa S, Pham CG, Zazzeroni F, Franzoso G. NF-kappaB and JNK: an intricate affair. Cell Cycle 2004;3:1524-9.
17. Bubici C, Papa S, Dean K, Franzoso G. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 2006;25:6731-48.
18. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factorkappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001;98:2301-7.
19. Ohyashiki JH, Kobayashi C, Hamamura R, Okabe S, Tauchi T, Ohyashiki K. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci 2009;100:970-7.
20. Kim JL, Kang HN, Kang MH, Yoo YA, Kim JS, Choi CW. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase. Acta Haematol 2011;126:241-5.
21. Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. Curr Med Chem 2005;12:2663-81.
22. Triantafyllou A, Liakos P, Tsakalof A, et al. The flavonoid quercetin induces hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits cell proliferation by depleting intracellular iron. Free Radic Res 2007;41:342-56.
23. Jung YS, Bae EY, Chung NG, et al. Comparison of immune responses induced by deferoxamine and deferasirox. Korean J Hematol 2008;43:150-8.
24. Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995;86:4295-306.
25. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733-7.
26. Valle P, Timeus F, Piglione M, et al. Effect of different exposures to desferrioxamine on neuroblastoma cell lines. Pediatr Hematol Oncol 1995;12:439-46.
27. Darnell G, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood 1999;94:781-92.
28. Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus Sci 2000;23:211-23.
29. Lescoat G, Chantrel-Groussard K, Pasdeloup N, Nick H, Brissot P, Gaboriau F. Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism. Cell Prolif 2007;40:755-67.
30. Chantrel-Groussard K, Gaboriau F, Pasdeloup N, et al. The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox. Eur J Pharmacol 2006;541:129-37.